 |
|
Renoprotective effects of febuxostat compared with allopurinol in patients with hyperuricemia: A systematic review and meta-analysis
Sollip Kim, Hyun-Jung Kim, Hyeong-Sik Ahn, Se Won Oh, Kum Hyun Han, Tae-Hyun Um, Chong-Rae Cho, Sang Youb Han
Kidney Res Clin Pract. 2017;36(3):274-281. Published online 2017 Sep 30 DOI: https://doi.org/10.23876/j.krcp.2017.36.3.274
|
|
Citations to this article as recorded by
 A Possible Therapeutic Application of the Selective Inhibitor of Urate Transporter 1, Dotinurad, for Metabolic Syndrome, Chronic Kidney Disease, and Cardiovascular Disease
Hidekatsu Yanai, Hiroki Adachi, Mariko Hakoshima, Sakura Iida, Hisayuki Katsuyama
Cells.2024; 13(5): 450. CrossRef Combination Treatment with Verinurad and Allopurinol in CKD: A Randomized Placebo and Active Controlled Trial
Hiddo J.L. Heerspink, Austin G. Stack, Robert Terkeltaub, Niels Jongs, Lesley A. Inker, Magnus Bjursell, Noha Maklad, Shira Perl, Olof Eklund, Tord Rikte, C. David Sjöström, Vlado Perkovic
Journal of the American Society of Nephrology.2024;[Epub] CrossRef Therapeutics in rheumatology and the kidney
Tommy Harty, Michelle O’Shaughnessy, Sinead Harney
Rheumatology.2023; 62(3): 1009. CrossRef Ameliorative Effect of Mannuronate Oligosaccharides on Hyperuricemic Mice via Promoting Uric Acid Excretion and Modulating Gut Microbiota
Biqian Wei, Pengfei Ren, Ruzhen Yang, Yuan Gao, Qingjuan Tang, Changhu Xue, Yuming Wang
Nutrients.2023; 15(2): 417. CrossRef Korean guidelines for the management of gout
Jennifer Jooha Lee, Ji Soo Lee, Min Kyung Chung, Joong Kyong Ahn, Hyo-Jin Choi, Seung-Jae Hong, Chong-Hyeon Yoon, Su-Hyun Kim, Kyung-Hwan Jeong, Jong-Woo Kim, Bo-Yeon Kim, Jin-Ho Shin, Woo Gyu Kim, Soo-Young Kim, Hyun-Jung Kim, Jeong-Soo Song, Jae-Bum Jun
Journal of Rheumatic Diseases.2023; 30(3): 141. CrossRef Korean guidelines for the management of gout
Jennifer Jooha Lee, Ji Soo Lee, Min Kyung Chung, Joong Kyong Ahn, Hyo-Jin Choi, Seung-Jae Hong, Chong-Hyeon Yoon, Su-Hyun Kim, Kyung-Hwan Jeong, Jong-Woo Kim, Bo-Yeon Kim, Jin-Ho Shin, Woo Gyu Kim, Soo-Young Kim, Hyun-Jung Kim, Jeong-Soo Song, Jae-Bum Jun
The Korean Journal of Internal Medicine.2023; 38(5): 641. CrossRef Febuxostat alleviates Arsenic Trioxide-Induced renal injury in Rats: Insights on the crosstalk between NLRP3/TLR4, Sirt-1/NF-κB/TGF-β signaling Pathways, and miR-23b-3p, miR-181a-5b expression
Basel A. Abdel-Wahab, Ehab A.M. El-Shoura, Mohammed Shafiuddin Habeeb, Dalia Zafaar
Biochemical Pharmacology.2023; 216: 115794. CrossRef Celebrating Versatility: Febuxostat’s Multifaceted Therapeutic Application
Krasimir Iliev Kraev, Mariela Gencheva Geneva-Popova, Bozhidar Krasimirov Hristov, Petar Angelov Uchikov, Stanislava Dimitrova Popova-Belova, Maria Ilieva Kraeva, Yordanka Mincheva Basheva-Kraeva, Nina Staneva Stoyanova, Vesela Todorova Mitkova-Hristova
Life.2023; 13(11): 2199. CrossRef Effectiveness and safety of different doses of febuxostat compared with allopurinol in the treatment of hyperuricemia: a meta-analysis of randomized controlled trials
Hong Xie, Nan Hu, Ting Pan, Jun-Cai Wu, Miao Yu, Deng-Chao Wang
BMC Pharmacology and Toxicology.2023;[Epub] CrossRef In vitro and in vivo ameliorative effects of polyphenols from purple potato leaves on renal injury and associated inflammation induced by hyperuricemia
Rui Sun, Juan Kan, Huahao Cai, Jinhai Hong, Changhai Jin, Man Zhang
Journal of Food Biochemistry.2022;[Epub] CrossRef Superior effect of allopurinol compared to febuxostat on the retardation of chronic kidney disease progression
Seokwoo Park, Jung Pyo Lee, Dong Ki Kim, Yon Su Kim, Chun Soo Lim, Karin Jandeleit-Dahm
PLOS ONE.2022; 17(2): e0264627. CrossRef Systematically Exploring the Chemical Ingredients and Absorbed Constituents of Polygonum capitatum in Hyperuricemia Rat Plasma Using UHPLC-Q-Orbitrap HRMS
Huanyu Guan, Pengfei Li, Qian Wang, Fanli Zeng, Daoping Wang, Mei Zhou, Meng Zhou, Xun He, Shanggao Liao, Weidong Pan
Molecules.2022; 27(11): 3521. CrossRef Efficacy and safety of urate-lowering agents in asymptomatic hyperuricemia: systematic review and network meta-analysis of randomized controlled trials
Tunlanut Sapankaew, Kunlawat Thadanipon, Narisa Ruenroengbun, Kamolpat Chaiyakittisopon, Atiporn Ingsathit, Pawin Numthavaj, Nathorn Chaiyakunapruk, Gareth McKay, John Attia, Ammarin Thakkinstian
BMC Nephrology.2022;[Epub] CrossRef Renoprotective and in silico Modeling Studies of Febuxostat in Gentamicin Induced Nephrotoxic Rats
Ali Alqahtani, Kumarappan Chidambara, Khalid Asseri, Krishnaraju Venkatesan, Absar Ahmed Qure, Afaf Aldahish, Taha Alqahtani, Yahia Alghazwani, Talha Bin Emran, Hesham M. Hassan, Saeed A. Asiri, Noohu Abdulla Kh, Pitchai Balakumar
International Journal of Pharmacology.2022; 18(5): 994. CrossRef Urate-lowering efficacy and renal safety of febuxostat in patients with hyperuricemia and stage 4–5 chronic kidney disease not yet on dialysis: A meta-analysis of observational studies
Hye-Jin Jeong, Woo Yeong Park, Sang-Hyon Kim, Nicola Dalbeth, Chang-Nam Son
Seminars in Arthritis and Rheumatism.2022; 56: 152073. CrossRef The effect of trajectory of serum uric acid on survival and renal outcomes in patients with stage 3 chronic kidney disease
Chia-Lin Lee, Cheng-Hsu Chen, Ming-Ju Wu, Shang-Feng Tsai
Medicine.2022; 101(30): e29589. CrossRef Therapeutic Strategies for the Treatment of Chronic Hyperuricemia: An Evidence-Based Update
Arrigo F. G. Cicero, Federica Fogacci, Masanari Kuwabara, Claudio Borghi
Medicina.2021; 57(1): 58. CrossRef Contentious Issues in Gout Management: The Story so Far
Mohamed Talaat, Kyle Park, Naomi Schlesinger
Open Access Rheumatology: Research and Reviews.2021; Volume 13: 111. CrossRef Effectiveness of Drug Treatments for Lowering Uric Acid on Renal Function in Patients With Chronic Kidney Disease and Hyperuricemia: A Network Meta-Analysis of Randomized Controlled Trials
Xiang Liu, Yuxuan Qiu, Duohui Li, Jiaxing Tan, Xiuping Liang, Wei Qin
Frontiers in Pharmacology.2021;[Epub] CrossRef Clinical Effects of Xanthine Oxidase Inhibitors in Hyperuricemic Patients
Arrigo F.G. Cicero, Federica Fogacci, Raffaele Ivan Cincione, Giuliano Tocci, Claudio Borghi
Medical Principles and Practice.2021; 30(2): 122. CrossRef Renoprotection with SGLT2 inhibitors in type 2 diabetes over a spectrum of cardiovascular and renal risk
Francesco Giorgino, Jiten Vora, Peter Fenici, Anna Solini
Cardiovascular Diabetology.2020;[Epub] CrossRef Management of asymptomatic hyperuricemia: Integrated Diabetes & Endocrine Academy (IDEA) consensus statement
Rahul Valsaraj, Awadhesh Kumar Singh, Kalyan Kumar Gangopadhyay, Biswajit Ghoshdastidar, Ghanshyam Goyal, Masood Batin, Dibyendu Mukherjee, Upal Sengupta, Sanjay Chatterjee, Nilanjan Sengupta
Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2020; 14(2): 93. CrossRef A treat-to-target approach for gout confers renoprotective effect in patients with chronic kidney disease stage 3
Marta Novella-Navarro, Jose Luis Cabrera-Alarcon, Cesar Diaz-Torne, Francisco Aramburu-Muñoz, Iustina Janta, Maria Carmen Ortega de la O, Alejandro Prada-Ojeda, Luis Sala-Icardo, Ana Urruticoechea-Arana, Paloma García de la Peña Lefebvre, Enrique Calvo-Ar
Rheumatology International.2020; 40(7): 1081. CrossRef A Lanosteryl Triterpene (RA-3) Exhibits Antihyperuricemic and Nephroprotective Effects in Rats
Nomadlozi Blessings Hlophe, Andrew Rowland Opoku, Foluso Oluwagbemiga Osunsanmi, Trayana Georgieva Djarova-Daniels, Oladipupo Adejumobi Lawal, Rebamang Anthony Mosa
Molecules.2020; 25(17): 4010. CrossRef Comparative effect of allopurinol and febuxostat on long-term renal outcomes in patients with hyperuricemia and chronic kidney disease: a systematic review
Anna M. Hu, Jamie N. Brown
Clinical Rheumatology.2020; 39(11): 3287. CrossRef Baseline characteristics of the autosomal‐dominant polycystic kidney disease sub‐cohort of the KoreaN cohort study for outcomes in patients with chronic kidney disease
Hyunsuk Kim, Junga Koh, Sue K Park, Kook H Oh, Yeong H Kim, Yaeni Kim, Curie Ahn, Yun K Oh
Nephrology.2019; 24(4): 422. CrossRef Effects of febuxostat on renal function in patients with chronic kidney disease
Tsu-Chen Lin, Lie Yee Hung, Ying-Chun Chen, Wei-Cheng Lo, Chun Hung Lin, Ka-Wai Tam, Mei-Yi Wu
Medicine.2019; 98(29): e16311. CrossRef Impact of urate-lowering drugs on the progression and recovery from chronic kidney disease among gout patients
Ting-Ting Chung, Kuang-Hui Yu, Chang-Fu Kuo, Shue-Fen Luo, Meng-Jiun Chiou, Wen-Ching Lan, Jung-Sheng Chen, Wen-Yi Tseng, Ao-Ho Hsieh, Lian-Chin Wang
Arthritis Research & Therapy.2019;[Epub] CrossRef Antioxidant, Anti-Melanogenic and Anti-Wrinkle Effects ofPhellinus vaninii
Kyung Hoan Im, Seung A Baek, Jaehyuk Choi, Tae Soo Lee
Mycobiology.2019; 47(4): 494. CrossRef Metabolomics analysis elucidates unique influences on purine / pyrimidine metabolism by xanthine oxidoreductase inhibitors in a rat model of renal ischemia-reperfusion injury
Takashi Tani, Ken Okamoto, Megumi Fujiwara, Akira Katayama, Shuichi Tsuruoka
Molecular Medicine.2019;[Epub] CrossRef Pharmacological urate-lowering approaches in chronic kidney disease
Xinrui Li, Jing Liu, Liang Ma, Ping Fu
European Journal of Medicinal Chemistry.2019; 166: 186. CrossRef Febuxostat and Cardiovascular Events: A Systematic Review and Meta-Analysis
John A. Cuenca, Javier Balda, Ana Palacio, Larry Young, Michael H. Pillinger, Leonardo Tamariz
International Journal of Rheumatology.2019; 2019: 1. CrossRef Xanthine Oxidase Inhibition by Febuxostat in Macrophages Suppresses Angiotensin II-Induced Aortic Fibrosis
Masateru Kondo, Masaki Imanishi, Keijo Fukushima, Raiki Ikuto, Yoichi Murai, Yuya Horinouchi, Yuki Izawa-Ishizawa, Mitsuhiro Goda, Yoshito Zamami, Kenshi Takechi, Masayuki Chuma, Yasumasa Ikeda, Hiromichi Fujino, Koichiro Tsuchiya, Keisuke Ishizawa
American Journal of Hypertension.2019; 32(3): 249. CrossRef Acute kidney injury associated with febuxostat and allopurinol: a post-marketing study
Amayelle Rey, Benjamin Batteux, Solène M. Laville, Justine Marienne, Kamel Masmoudi, Valérie Gras-Champel, Sophie Liabeuf
Arthritis Research & Therapy.2019;[Epub] CrossRef Effects of febuxostat on serum cytokines IL‑1, IL‑4, IL‑6, IL‑8, TNF‑α and COX‑2
Guohua Hao, Wei Duan, Jianping Sun, Jingyao Liu, Bo Peng
Experimental and Therapeutic Medicine.2018;[Epub] CrossRef Anti-fibrotic treatments: A review of clinical evidence
Marco Allinovi, Letizia De Chiara, Maria Lucia Angelotti, Francesca Becherucci, Paola Romagnani
Matrix Biology.2018; 68-69: 333. CrossRef The potential renoprotection of xanthine oxidase inhibitors: Febuxostat versus allopurinol
Dong-Ryeol Ryu
Kidney Research and Clinical Practice.2017; 36(3): 207. CrossRef
|